Proximal CD13 Versus Distal GATA-3 Expression in Renal Neoplasia According to WHO 2016 Classification

Little is known about the aminopeptidase CD13 in renal neoplasia according to the new 2016 World Health Organization renal tumor classification. We selected 175 cases, including 79 clear cell, 31 papillary, 24 chromophobe, 8 clear cell papillary renal cell carcinomas (RCCs), 21 oncoytomas, and 12 microphthalmia transcription factor family translocation RCCs: 4 t(6;11)/transcription factor EB (TFEB), 7 t(Xp11) with 2 cystic variants and 1 t(X;17). GATA binding protein 3 (GATA-3) was inserted as control. Expression of proximal antigen CD13 was observed in 63/79 (80%) clear cell, 25/31 (81%) papillary, 3/8 (37%) clear cell papillary, 1/4 (25%) t(6;11)/TFEB, 2/7 (28%) cystic t(Xp11), and in 1/1 t(X;17) RCCs. All chromophobe RCC (0/24) and all oncocytomas (0/21) resulted negative. CD10 was seen in 76/79 (96%) clear cell, 15/31 (48%) papillary, 10/24 (42%) chromophobe, 1/8 (12%) clear cell papillary RCCs, 4/21 (19%) oncocytomas, 1/4 (25%) t(6;11)/TFEB, 2/7 (29%) cystic t(Xp11), and in 1/1 t(X;17) RCCs. GATA-3 was positive in 3/7 (42%) clear cell papillary RCCs and negative in all remaining RCCs, except a single chromophobe RCC and a single oncocytoma. We concluded that: (1) CD13 and GATA-3 immunostains may serve as a diagnostic aid in differentiating subtypes of RCC; (2) CD13 is always absent in chromophobe RCC and oncocytomas, whereas CD10 can be immunoexpressed in both; (3) CD13 should be included in a panel of antibodies to distinguish “proximal renal tumors” from “distal renal tumors” and between clear cell RCC versus microphthalmia transcription factor family translocations RCCs; and (4) when present, GATA-3 is specific for clear cell papillary RCC.

[1]  H. Eguchi,et al.  A CD13 inhibitor, ubenimex, synergistically enhances the effects of anticancer drugs in hepatocellular carcinoma , 2016, International journal of oncology.

[2]  Y. Kajiyama,et al.  Aminopeptidase N (APN/CD13) as a target molecule for scirrhous gastric cancer , 2016, Clinics and Research in Hepatology and Gastroenterology.

[3]  B. Bauvois,et al.  Aminopeptidase‐N/CD13 is a potential proapoptotic target in human myeloid tumor cells , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[4]  R. Larsson,et al.  Aminopeptidase N (CD13) as a target for cancer chemotherapy , 2011, Cancer science.

[5]  B. Delahunt,et al.  Outcome prediction for renal cell carcinoma: evaluation of prognostic factors for tumours divided according to histological subtype , 2007, Pathology.

[6]  D. Bostwick,et al.  Immunohistochemical analysis of chromophobe renal cell carcinoma, renal oncocytoma, and clear cell carcinoma: an optimal and practical panel for differential diagnosis. , 2007, Archives of Pathology & Laboratory Medicine.

[7]  Liang Cheng,et al.  Role of molecular markers in diagnosis and prognosis of renal cell carcinoma. , 2007, Analytical and quantitative cytology and histology.

[8]  D. Barocas,et al.  Renal cell carcinoma sub‐typing by histopathology and fluorescence in situ hybridization on a needle‐biopsy specimen , 2007, BJU international.

[9]  T. Nakajima,et al.  Immunohistochemical expression of aminopeptidase N (CD13) in human lung squamous cell carcinomas, with special reference to Bestatin adjuvant therapy , 2006, Pathology international.

[10]  T. Lebret,et al.  Evaluation of imaging-guided fine-needle percutaneous biopsy of renal masses , 2005, European Radiology.

[11]  S. Mills,et al.  KIT and RCC Are Useful in Distinguishing Chromophobe Renal Cell Carcinoma From the Granular Variant of Clear Cell Renal Cell Carcinoma , 2005, The American journal of surgical pathology.

[12]  Yurika Saitoh,et al.  Anti-tumor angiogenesis effect of aminopeptidase inhibitor bestatin against B16-BL6 melanoma cells orthotopically implanted into syngeneic mice. , 2004, Cancer letters.

[13]  P. Tamboli,et al.  Chromophobe renal cell carcinoma: a comparative study of histological, immunohistochemical and ultrastructural features using high throughput tissue microarray , 2004, Histopathology.

[14]  J. Eble,et al.  CD10 is expressed in a subset of chromophobe renal cell carcinomas , 2004, Modern Pathology.

[15]  C. Pan,et al.  The diagnostic utility of MOC31, BerEP4, RCC marker and CD10 in the classification of renal cell carcinoma and renal oncocytoma: an immunohistochemical analysis of 328 cases , 2004, Histopathology.

[16]  P. Rehak,et al.  CD10 is a diagnostic and prognostic marker in renal malignancies , 2004, Histopathology.

[17]  J. Cheville,et al.  Comparisons of Outcome and Prognostic Features Among Histologic Subtypes of Renal Cell Carcinoma , 2003, The American journal of surgical pathology.

[18]  M. Terris,et al.  Gene expression patterns in renal cell carcinoma assessed by complementary DNA microarray. , 2003, The American journal of pathology.

[19]  S. Kim,et al.  Immunohistochemical Profile of Common Epithelial Neoplasms Arising in the Kidney , 2002, Applied immunohistochemistry & molecular morphology : AIMM.

[20]  Mahul B. Amin,et al.  Prognostic Impact of Histologic Subtyping of Adult Renal Epithelial Neoplasms: An Experience of 405 Cases , 2002, The American journal of surgical pathology.

[21]  Gaetano Mobilio,et al.  Prognostic Value of Renal Cell Carcinoma Nuclear Grading: Multivariate Analysis of 333 Cases , 2001, Urologia Internationalis.

[22]  M. Jewett,et al.  The natural history of small renal masses. , 2000, Nature clinical practice. Urology.

[23]  H. Moch,et al.  Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma , 2000, Cancer.

[24]  P. Chu,et al.  Paraffin-section detection of CD10 in 505 nonhematopoietic neoplasms. Frequent expression in renal cell carcinoma and endometrial stromal sarcoma. , 2000, American journal of clinical pathology.

[25]  A. Renshaw,et al.  Use of antibodies to RCC and CD10 in the differential diagnosis of renal neoplasms. , 2000, The American journal of surgical pathology.

[26]  A. Kehlen,et al.  CD13—not just a marker in leukemia typing , 1999, Immunology Today.

[27]  A. Taylor.  Aminopeptidases: structure and function , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[28]  A. Newland,et al.  The significance of aminopeptidases and haematopoietic cell differentiation , 1992, Blood Reviews.

[29]  J. Gogusev,et al.  Expression of the human nephron differentiation molecules in renal cell carcinomas. , 1990, The American journal of pathology.

[30]  R. Metzgar,et al.  Characterization of renal neoplasms with monoclonal antibodies to leukocyte differentiation antigens , 1986, Cancer.

[31]  P. Watson,et al.  NCL-CD10-270: a new monoclonal antibody recognizing CD10 in paraffin-embedded tissue. , 1999, The American journal of pathology.

[32]  G. Pallesen,et al.  Expression of segment-specific antigens in the human nephron and in renal epithelial tumors. , 1988, APMIS. Supplementum.

[33]  Á.,et al.  Hematopoietic Differentiation Antigens That Are Membrane-Associated Enzymes : Cutting Is the Key ! , 2022 .